Status:
COMPLETED
Nefazodone in the Treatment of Social Phobia
Lead Sponsor:
Emory University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Social Anxiety Disorder (SAD)
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
Detailed Description
The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65
Exclusion
- A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
April 1 2000
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00231348
End Date
April 1 2000
Last Update
November 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Depatment of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States, 30322